ALCON RESEARCH

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)

First Posted Date
2003-01-07
Last Posted Date
2012-11-28
Lead Sponsor
Alcon Research
Target Recruit Count
291
Registration Number
NCT00051129

A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension

Phase 2
Completed
Conditions
Glaucoma, Open-angle
Ocular Hypertension
First Posted Date
2003-01-07
Last Posted Date
2012-04-16
Lead Sponsor
Alcon Research
Registration Number
NCT00051194
Locations
🇺🇸

Europe, Fort Worth, Texas, United States

A Long-term Safety Study of Once-daily Travatan

Phase 3
Completed
Conditions
Glaucoma, Open-angle
Ocular Hypertension
Interventions
Drug: Travatan
First Posted Date
2003-01-07
Last Posted Date
2011-10-07
Lead Sponsor
Alcon Research
Target Recruit Count
502
Registration Number
NCT00051168
Locations
🇺🇸

Europe, Fort Worth, Texas, United States

A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)

Phase 3
Completed
Conditions
Glaucoma, Open-Angle
Ocular Hypertension
First Posted Date
2003-01-07
Last Posted Date
2008-08-05
Lead Sponsor
Alcon Research
Registration Number
NCT00051155
Locations
🇺🇸

Europe, Fort Worth, Texas, United States

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

First Posted Date
2003-01-07
Last Posted Date
2008-08-05
Lead Sponsor
Alcon Research
Registration Number
NCT00051181
Locations
🇺🇸

Asia, Fort Worth, Texas, United States

🇦🇺

Australia, Sidney, Australia

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Phase 3
Completed
Conditions
Glaucoma, Open-Angle
Ocular Hypertension
First Posted Date
2003-01-07
Last Posted Date
2008-08-05
Lead Sponsor
Alcon Research
Registration Number
NCT00051142
Locations
🇺🇸

Latin America, Fort Worth, Texas, United States

Study of TRAVATAN in Subjects With Iris Pigmentation Changes

First Posted Date
2002-10-18
Last Posted Date
2013-05-15
Lead Sponsor
Alcon Research
Target Recruit Count
336
Registration Number
NCT00047554

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-69

Phase 3
Completed
Conditions
Ocular Hypertension
Open-Angle Glaucoma
First Posted Date
2002-10-18
Last Posted Date
2008-08-05
Lead Sponsor
Alcon Research
Registration Number
NCT00047515
Locations
🇺🇸

Clinical Trial Sites, Multiple Locations Throughout the United States, Texas, United States

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41

Phase 3
Completed
Conditions
Open-Angle Glaucoma
Ocular Hypertension
First Posted Date
2002-10-18
Last Posted Date
2008-08-05
Lead Sponsor
Alcon Research
Registration Number
NCT00047528
Locations
🇺🇸

Clinical Trial Sites, Fort Worth, Texas, United States

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70

Phase 3
Completed
Conditions
Ocular Hypertension
Open-Angle Glaucoma
First Posted Date
2002-10-18
Last Posted Date
2008-08-05
Lead Sponsor
Alcon Research
Registration Number
NCT00047541
Locations
🇺🇸

Clinical Trial Sites, Fort Worth, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy